Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus

The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model

(2015) Yusuke Nakatsu et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease

(2015) André J. Scheen   CLINICAL PHARMACOKINETICS

Historical cohort analysis of treatment patterns for patients with type 2 diabetes initiating metformin monotherapy

(2015) Leslie Hazel-Fernandez et al.   CURRENT MEDICAL RESEARCH AND OPINION

Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes

(2015) M. D. Sharma   DIABETES OBESITY & METABOLISM

Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats

(2015) Yuka Hayashizaki-Someya et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion

(2015) Caroline Bonner et al.   NATURE MEDICINE

Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis

(2015) Haoda Fu et al.   Diabetes Therapy

Early Glycemic Response Predicts Achievement of Subsequent Treatment Targets in the Treatment of Type 2 Diabetes: A Post hoc Analysis

(2015) Haoda Fu et al.   Diabetes Therapy

Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models

(2014) M Suzuki et al.   Nutrition & Diabetes

Guidelines adherence in the treatment of patients with newly diagnosed type 2 diabetes: a historical cohort comparing the use of metformin in Quebec pre and post-Canadian Diabetes Association guidelines

(2013) Ting-Yu Wang et al.   BMC HEALTH SERVICES RESEARCH

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice

(2013) Atsuo Tahara et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Role of Pin1 Protein in the Pathogenesis of Nonalcoholic Steatohepatitis in a Rodent Model

(2012) Yusuke Nakatsu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models

(2012) Yin Liang et al.   PLoS One

Animal models in nonalcoholic steatohepatitis research: utility and clinical translation

(2011) Quentin M. Anstee   LIVER INTERNATIONAL

(1S)-1,5-Anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol (TS-071) is a Potent, Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for Type 2 Diabetes Treatment

(2010) Hiroyuki Kakinuma et al.   JOURNAL OF MEDICINAL CHEMISTRY

The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome

(2010) Jung Sub Lim et al.   Nature Reviews Gastroenterology & Hepatology

Animal models of NASH: Getting both pathology and metabolic context right

(2008) Claire Z Larter et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY